Compare Amylx Pharmaceuticals Inc (AMLX) vs New York Times Co (NYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs New York Times Co — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while New York Times Co trades at $75 (market cap $12.13B). The key difference: New York Times Co is far larger — about 6.1× Amylx Pharmaceuticals Inc's market cap, and New York Times Co pays a 1.23% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | NYT | |
|---|---|---|
Market Cap | $1.98B | $12.13B |
Sector | Health | Media |
52-Week High | $18.70 | $85.86 |
52-Week Low | $7.64 | $51.43 |
Enterprise Value | $1.70B | $11.53B |
Dividend Yield | — | 1.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
The New York Times (NYT) stock trades at $74.96, up 0.89% on the day, reflecting steady growth. Recent earnings have consistently beaten estimates, with Q1 2026 EPS of $0.61 surpassing the $0.47 expectation. Revenue reached $2.82B in 2025, with net income margin improving to 12.17%. Technical indicators show a bullish trend, while analyst consensus is a $78 price target. Recent news highlights legal actions involving OpenAI and government subpoenas, adding to operational scrutiny.
Outlook remains positive due to strong earnings performance and revenue growth, but risks include legal battles and regulatory pressures. The stock offers potential upside to the consensus target, supported by solid cash flow and profitability metrics. Investors should weigh these factors against ongoing litigation and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
